“…13,15 Based on the single-agent activity of these drugs, the preferential toxicity profile, and a potentially higher therapeutic index than that of cisplatin, 5-FU, or methotrexate in patients with recurrent or metastatic SCCHN, we conducted a Phase II study combining paclitaxel, ifosfamide, and cisplatin (TIP) to treat these patients. 16 The regimen produced documented high overall response rates including prolonged duration of CR and encouraging median and 1 and 2-year median survival rates. 16 However, the TIP regimen induced significant degrees of peripheral neuropathy, fatigue, emesis, and anorexia, particularly when patients received more than four to six courses of treatment.…”